Details for New Drug Application (NDA): 074406
✉ Email this page to a colleague
NDA 074406 describes SUFENTANIL CITRATE, which is a drug marketed by Hikma, Hospira, and Watson Labs, and is included in three NDAs. It is available from two suppliers. Additional details are available on the SUFENTANIL CITRATE profile page.
The generic ingredient in SUFENTANIL CITRATE is sufentanil citrate. There are nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the sufentanil citrate profile page.
The generic ingredient in SUFENTANIL CITRATE is sufentanil citrate. There are nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the sufentanil citrate profile page.
Summary for 074406
| Tradename: | SUFENTANIL CITRATE |
| Applicant: | Watson Labs |
| Ingredient: | sufentanil citrate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 074406
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 0.05MG BASE/ML | ||||
| Approval Date: | Dec 15, 1995 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
